BeiGene (BGNE) announced its intent to change the company’s name to “BeOne Medicines Ltd.,” confirming its commitment to develop innovative medicines to eliminate cancer by partnering with the global community to serve as many patients as possible. The new name is part of a broader strategic growth plan that has enabled the company’s global oncology leadership since its inception in 2010. The company recently reported $1B in quarterly total revenue driven by strong growth in product revenue in the U.S. and Europe. To support its expansive clinical portfolio and global growth, the company opened its $800M flagship clinical R&D and manufacturing facility at the Princeton West Innovation Campus in Hopewell, N.J. in July. Once the name is approved by shareholders, the company’s stock ticker on Nasdaq will change to “ONC”.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BGNE:
- BeiGene Reports Strong Revenue Growth in Q3 2024
- BeiGene price target raised to $260 from $254 at TD Cowen
- BeiGene’s Financial and Market Challenges: Navigating Risks in Drug Acceptance, Competition, and Geopolitical Tensions
- BeiGene reports Q3 EPS ($1.15), consensus ($1.20)
- BeiGene, Ltd. (BGNE) Q3 Earnings Cheat Sheet